Edmond DE Rothschild Holding S.A. grew its position in shares of Kamada Ltd. (NASDAQ:KMDA) by 10.5% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 42,200 shares of the biotechnology company’s stock after buying an additional 4,000 shares during the quarter. Edmond DE Rothschild Holding S.A. owned approximately 0.12% of Kamada worth $251,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Separately, Renaissance Technologies LLC lifted its holdings in shares of Kamada by 16.7% during the 1st quarter. Renaissance Technologies LLC now owns 264,800 shares of the biotechnology company’s stock valued at $1,801,000 after buying an additional 37,800 shares during the last quarter. Hedge funds and other institutional investors own 7.29% of the company’s stock.
Kamada Ltd. (NASDAQ KMDA) opened at 4.70 on Thursday. Kamada Ltd. has a 52 week low of $3.75 and a 52 week high of $8.61. The company has a 50 day moving average price of $4.49 and a 200-day moving average price of $6.19. The company’s market capitalization is $175.78 million.
Kamada (NASDAQ:KMDA) last issued its quarterly earnings results on Tuesday, August 1st. The biotechnology company reported $0.13 EPS for the quarter, beating the consensus estimate of $0.12 by $0.01. Kamada had a negative return on equity of 2.94% and a negative net margin of 2.24%. The firm had revenue of $32.55 million during the quarter, compared to analysts’ expectations of $33.30 million. During the same period in the prior year, the firm posted ($0.04) earnings per share. The business’s quarterly revenue was up 70.7% compared to the same quarter last year. On average, equities analysts anticipate that Kamada Ltd. will post $0.09 earnings per share for the current fiscal year.
A number of brokerages recently weighed in on KMDA. Jefferies Group LLC reissued a “buy” rating and issued a $7.00 price objective (down from $9.00) on shares of Kamada in a research note on Wednesday, August 2nd. TheStreet downgraded Kamada from a “c-” rating to a “d+” rating in a research note on Tuesday, August 1st. Zacks Investment Research raised Kamada from a “sell” rating to a “hold” rating in a research note on Tuesday, August 15th. Finally, ValuEngine downgraded Kamada from a “hold” rating to a “sell” rating in a research note on Friday, September 1st. One analyst has rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $7.67.
Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.
Want to see what other hedge funds are holding KMDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kamada Ltd. (NASDAQ:KMDA).
Receive News & Ratings for Kamada Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.